How Dr. Marek Polák Is Fixing One of Biotech’s Most Expensive Bottlenecks

How Dr. Marek Polák Is Fixing One of Biotech’s Most Expensive Bottlenecks

We all know someone waiting on a medical breakthrough. It could be a parent battling a chronic illness, a colleague pushing through long workdays while managing treatment, or a child whose options have not changed in decades. And while the human cost is clear, there is also a business cost that is just as real. Slow drug development pulls people out of the workforce, raises insurance premiums, and forces companies to absorb productivity losses t…